952747-32-9

Basic information

• Product Name: (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine
• Synonyms: (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine;Hydroxylamine, O-[(2R)-2-pyrrolidinylmethyl]-, dihydrochloride
• CAS NO: 952747-32-9
• Molecular Formula: C5H12N2O.2HCl
• Molecular Weight: 116.16
• Mol File: 952747-32-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine(952747-32-9)
• EPA Substance Registry System: (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine(952747-32-9)

Safety Data

• Hazardous Substances Data: 952747-32-9(Hazardous Substances Data)

Usage

General Description

(R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine is a chemical compound with the molecular formula C6H12N2O. It is an organic compound that contains a hydroxylamine functional group, which is a derivative of ammonia. The compound has a chiral center, indicated by the (R) in its name, which means it has two enantiomeric forms. (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine is commonly used in organic synthesis as a chiral auxiliary for the asymmetric synthesis of various compounds, particularly in the pharmaceutical industry. It can also act as a ligand in transition metal-catalyzed asymmetric synthesis reactions. Additionally, (R)-O-(pyrrolidin-2-ylmethyl)hydroxylamine has potential applications in the development of new drugs and medicinal compounds due to its chiral nature and ability to influence the stereochemistry of a reaction.

Upstream product

• 863991-04-2 2-aminooxymethyl-(S)-pyrrolidine-1-carboxylic acid t-butyl ester 
• 863991-05-3 (R)-tert-butyl 2-(aminooxymethyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Novel analogues of istaroxime, a potent inhibitor of Na+,K +-ATPase: Synthesis and structure-activity relationship

We report the synthesis and biological properties of novel inhibitors of the Na+,K+-ATPase as positive inotropic compounds. Following our previously described model from which Istaroxime was generated, the 5α,14α-androstane skeleton was used as a scaffold to study the space around the basic chain of our lead compound. Some compounds demonstrated higher potencies than Istaroxime on the receptor and the (E)-3-[(R)-3- pyrrolidinyl]oxime derivative, 15, was the most potent; as further confirmation of our model, the E isomers of the oxime are more potent than the Z form. The compounds tested in the guinea pig model induced positive inotropic effects, which are correlated to the in vitro inhibitory potency on the Na +,K+-ATPase. The finding that all tested compounds resulted less proarrhythmogenic than digoxin, a currently clinically used positive inotropic agent, suggests that this could be a feature of the 3-aminoalkyloxime derivative class of 5α,14α-androstane.